Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer

Chimeric antigen receptor (CAR) T cell therapy has transformed cancer treatment, but its efficacy remains limited in solid tumors due to antigen heterogeneity, an immunosuppressive microenvironment, and the glycocalyx barrier. The glycocalyx, composed of dense glycoproteins such as MUC1, is markedly expanded in cancers, where it impedes immune cell access and antigen engagement, thereby reducing therapeutic efficacy. In most adenocarcinomas, the Tn antigen, comprising N-acetylgalactosamine linked to serine or threonine, is overexpressed. Tn-MUC1, a truncated form of MUC1 decorated with Tn antigen, is frequently overexpressed in pancreatic cancer. Here, we incorporate a non-signaling glyco-bridge binder recognizing Tn-MUC1 into mesothelin-directed CAR-T cells. This bridge enhances tumor recognition and cytotoxicity by increasing avidity and facilitating CAR activation in a density- and affinity-dependent manner. To directly validate these effects at the cell interaction level, we used Lumicks z-Movi to quantify CAR-T binding strength to tumor targets. CAR-T cells equipped with the Tn-MUC1 glyco-bridge exhibited higher cell avidity toward Tn-MUC1-expressing tumor cells compared to a CD19 bridge control. To broaden its applicability, we design a tandem Helix pomatia agglutinin (HPA) lectin-based bridge that recognizes Tn antigens across cancer types. CAR-T cells with the HPA-bridge exhibit superior cytotoxicity in pancreatic cancer models.

‍

This webinar + Q&A will be available at two timeslots on February 23rd to accommodate global-friendly time zones. You can choose between the options upon registration below:

1. Europe & Americas-friendly Time Zone: 17:00 UCT+1
2. Asia-Pacific and Australia-friendly Time Zone: 09:00 UCT+8